布地奈德联合复方异丙托溴铵对慢性阻塞性肺疾病急性加重期患者的疗效及其对炎症指标的影响  

Budesonide combined compound isopropyl bromide bracket for the curative effect of patients with acute exacerbation of chronic obstructive pulmonary disease and its effects on peripheral blood NLR,PLR and SII

作　　者：王锻 尤雅 Wang Duan;You Ya(Department of Pharmacy,Northwest University First Hospital,Xi’an Shaanxi 710043,China;Department of Respiratory and Critical Care Medicine,Northwest University First Hospital,Xi’an Shaanxi 710043,China)

机构地区：[1]西北大学第一医院药学部,陕西西安710043 [2]西北大学第一医院呼吸与危重症医学科,陕西西安710043

出　　处：《中国医刊》2025年第4期423-426,共4页Chinese Journal of Medicine

基　　金：陕西省重点研发计划(2020SF-924)。

摘　　要：目的探讨布地奈德联合复方异丙托溴铵对慢性阻塞性肺疾病急性加重期(AECOPD)患者的治疗效果及对外周血中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)和系统性免疫炎症指数(SII)的影响。方法纳入2019年4月至2022年3月就诊于西北大学第一医院的121例AECOPD患者作为研究对象,按照随机数字表法将其分为对照组(n=61)与观察组(n=60)。两组患者均给予吸氧、祛痰、平喘、抗感染治疗。对照组在此基础上给予复方异丙托溴铵雾化吸入治疗,观察组在对照组的基础上给予布地奈德混悬液雾化吸入治疗,两组均连续治疗7 d。收集两组治疗前的临床资料,对比两组的临床疗效、治疗前后的肺功能[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气流量峰值(PEF)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)]、炎症因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)]及NLR、PLR、SII。结果观察组治疗显效率为55.00%,明显高于对照组的18.03%,差异有统计学意义(P<0.05)。治疗后,两组FVC、FEV1、PEF、FEV1/FVC均较治疗前增高,且观察组明显高于对照组,两组IL-6、CRP、NLR、PLR、SII水平均较治疗前降低,且观察组明显低于对照组,差异有统计学意义(P<0.05)。结论布地奈德联合复方异丙托溴铵治疗AECOPD患者可促进患者肺功能恢复,有效降低炎症水平。Objective To investigate the efficacy of budesonide combined with compound ipratropium bromide in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and its effects on peripheral blood neutrophil-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR)and systemic immune inflammatory index(SII).Method A total of 121 patients with acute exacerbation of COPD admitted to Northwest University First Hospital from April 2019 to March 2022 were selected as research objects and divided into control group(n=61)and observation group(n=60)according to random number table method.Both groups of patients were given oxygen inhalation,expectorant phlegm,asthma,anti-infection treatment.The control group was given atomized inhalation of compound ipratropium bromide on the basis of conventional treatment,and the observation group was given atomized inhalation of budesonide suspension on the basis of control group,and both groups were treated continuously for 7 days.The clinical data of the two groups before treatment were collected,and the clinical efficacy and lung function[forced vital capacity(FVC),forced expiratory volume in thefirst second(FEV1),peak expiratoryflow(PEF),forced expiratory volume in thefirst second/forced vital capacity in thefirst second(FEV1/FVC)],Inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)]and inflammatory index[neutrophil lymphocyte ratio(NLR),platelet lymphocyte ratio(PLR),systemic immune-inflammatory index(SII)]before and after treatment were compared.Result The treatment efficiency of the observation group was 55.00%,significantly higher than the 18.03%in the control group,with a statistically significant difference(P<0.05).After treatment,both groups showed increased FVC,FEV1,PEF,and FEV1/FVC values compared to before treatment,and the observation group was notably higher than the control group.Both groups also experienced a decrease in IL-6,CRP,NLR,PLR,and SII levels compared to before treatment,with the observation group showing a lower level than the c

关 键 词：布地奈德 复方异丙托溴铵 慢性阻塞性肺疾病急性加重期 系统性免疫炎症指数 

分 类 号：R563[医药卫生—呼吸系统]